Skip to main content

Table 3 Clinically meaningful response in surrogate endpoints in ischemic heart failure trials

From: Endpoints in stem cell trials in ischemic heart failure

Symptoms

Functional domain

LV function remodeling

Quality of life

A change in NYHA class

a) Increase of 50 m in 6-min walk test b) Increase of 10 % in VO2max

a) Increase of 5 % in absolute LVEF or; b) Decrease of 20 mL or 20 % (whichever is greater) in LVESV c) Decrease in NTproBNP by 35 % or 300 pg/ml, whichever is greater

a) Improvement in MLHF-Q ≥10 b) Improvement in KCCQ ≥20

  1. KCCQ Kansas City Cardiomyopathy Questionnaire, LV left ventricular, LVEF left ventricular ejection fraction, LVESV left ventricular end-systolic volume, MLHF Minnesota Living with Heart Failure Questionnaire, NTproBNP N-terminal pro-brain natriuretic peptide, NYHA New York Heart Association, VO 2max , maximal oxygen consumption